查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1925086

全球神经发育障碍数位疗法市场预测（至2032年），按产品类型、残疾类型、最终用户和地区划分

Digital Therapeutics for Neurodevelopmental Disorders Market Forecasts to 2032 - Global Analysis By Product Type, Disorder Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球用于治疗神经发育障碍的数位疗法市场价值将达到 4,800 万美元，预计到 2032 年将达到 2.0444 亿美元。

预计在预测期内，针对神经发育障碍的数位疗法将以23.0%的复合年增长率成长。这些数位疗法利用技术手段，帮助患有註意力不足过动症（ADHD）、自闭症和学习障碍等疾病的个体改善行为、认知和情绪调节能力。这些检验的数位工具透过行动应用程式、虚拟实境体验和游戏化练习提供个人化干预，从而实现持续评估和即时回馈。它们与传统治疗方法相辅相成，提高了患者的参与度，并提供灵活且便利的远距医疗服务。这些解决方案在诊所和家庭中的日益普及，正在改善早期治疗、提高治疗依从性和整体治疗效果，并提供数据驱动的指导，从而改变神经发育障碍的有效监测和管理方式。

一项针对 31 项研究（涉及 2169 名患有 ADHD 的儿童和青少年）进行的Meta分析发现，与对照组相比，数位治疗性介入显着改善了注意力不集中症状和反应时间，以及执行功能和工作记忆，表明其具有潜在的临床效用。

提高看护者和临床医生的意识和接受度

家长、看护者和医疗专业人员对数位疗法的理解和接受度不断提高，正在推动市场成长。临床试验证据和积极的患者疗效增强了人们对这些干预措施的信心。看护者重视便利、远距和高效的治疗方案，临床医师则将其视为标准疗法的宝贵补充。医疗服务提供者日益增长的信任和支持正在推动数位疗法的应用，并刺激进一步的研发，从而促进基于技术的神经发育障碍治疗方法的广泛应用，并推动市场扩张。

临床检验有限和监管方面的挑战

限制神经发育障碍数位疗法发展的主要挑战在于缺乏长期临床证据和监管路径不明朗。许多解决方案的检验有限，导致医疗专业人员在推荐时持谨慎态度。各国监管政策的不一致造成了核准、报销政策和法律合规的不确定性。由于临床医生优先考虑已确立的、经临床验证的治疗方法，数位替代疗法的普及速度仍然缓慢。此外，缺乏标准化的评估方法也降低了人们对治疗结果的信心。这些监管和检验的不足延缓了商业化进程，并限制了数位治疗方法在传统医疗体系中的广泛应用。

扩展远端医疗和远距护理模式

远端医疗和虚拟照护的日益普及为神经发育障碍管理领域的数位疗法创造了强劲的成长机会。数位平台使治疗能够在医院之外进行，让患者在家中即可接受个人化介入。这种模式支持持续监测、早期诊断和长期治疗，同时最大限度地减少了出行和基础设施的限制。医疗服务的改善惠及农村和医疗资源匮乏地区，扩大了市场覆盖范围。随着远距医疗的普及，数位疗法可以轻鬆整合到远距医疗框架中，从而推动更广泛的应用，并加强神经发育障碍的长期照护策略。

来自传统疗法和替代疗法的竞争

数位疗法面临的主要威胁之一是传统疗法的主导地位，例如行为疗法和药物治疗，这些疗法已被广泛信任并被常规使用。由于多年的临床检验和成熟的治疗路径，医护人员和看护者往往更倾向于面对面的治疗方法。替代疗法和辅助疗法的存在进一步加剧了这种压力，使得数位解决方案难以被接受。这种激烈的竞争可能会限制数位疗法的普及率，降低患者的转换意愿，并减缓数位疗法在神经发育障碍治疗领域的整体发展。

新冠疫情的影响：

新冠疫情的爆发对神经发育障碍的数位疗法市场产生了显着的正面影响，促使治疗模式转向远端解决方案。人际接触的限制扰乱了传统的治疗服务，使得居家和虚拟治疗方案的需求变得迫切。在长期封锁期间，数位疗法成为维持治疗流程、追踪患者进度和支持看护者的有效手段。人们对心理和发育健康的日益关注进一步促进了技术主导治疗的普及。疫情加速了数位疗法的应用，增加了资金筹措，并提高了监管的柔软性，从而巩固了数位疗法在未来神经发育障碍管理中的关键作用。

预计在预测期内，行动应用领域将占据最大的市场份额。

由于行动应用具有高度便利性和广泛的普及性，预计在预测期内，行动应用领域将占据最大的市场份额。这些解决方案专为主流智慧型手机和平板电脑设计，提供以行为、认知和情感发展为重点的个人化治疗活动。其使用者友善性使得儿童、看护者和临床医生能够在传统医疗机构之外继续进行治疗。行动应用还支援持续的进度追踪和远端监督，从而增强治疗的连续性。凭藉其简洁性、适应性和高用户参与度，行动应用比更复杂的技术更受欢迎，巩固了主导地位。

预计在预测期内，患者群体将在神经发育障碍领域中实现最高的复合年增长率。

在预测期内，患者群体预计将成为神经发育障碍领域中成长最快的群体，这主要得益于患者能够更便捷地直接参与技术赋能的治疗方案。智慧型手机和数位平台的普及使得患者能够在传统医疗机构之外积极参与治疗。互动式、个人化的治疗内容能够提高患者的参与度和长期依从性。随着患者赋能和居家照护的重要性日益凸显，对便利且灵活的数位化治疗方案的需求持续成长。公众意识的提高、对数位健康工具的日益亲和性以及对个人化护理模式的关注，正在加速数位化治疗方案的普及，使患者群体成为最具增长潜力的领域。

占比最大的地区：

在预测期内，北美预计将占据最大的市场份额，这得益于其先进的医疗保健体系和数位健康技术的快速应用。智慧型设备的普及率高、远距远端医疗框架完善以及医疗专业人员的高度认知，正在推动数位疗法的广泛应用。有利的政策支持、持续的创新以及对儿童和精神健康解决方案的大量投资，都巩固了该地区的主导地位。对早期疗育和个人化医疗的重视，进一步推动了数位疗法的应用。这些因素共同造就了北美强大的市场地位和持续的领先优势，使其成为全球神经发育护理领域数位疗法应用的最大贡献者。

预计年复合成长率最高的地区：

预计亚太地区在预测期内将实现最高的复合年增长率，这主要得益于数位化普及和医疗保健现代化进程的加速。行动装置的普及和网路连线的增强，使得基于应用程式和远端医疗解决方案的取得更加便捷。人们对发展障碍的认识不断提高，加上相关数位健康计画的推广，正在推动看护者和医疗保健提供者采用这些解决方案。该地区大规模的儿童人口以及对经济实惠且扩充性的护理解决方案的需求，进一步推动了数位疗法的市场成长。这些因素共同作用，使亚太地区成为数位疗法成长最快的市场。

免费客製化服务：

购买此报告的客户可以选择以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要参与者（最多3家公司）的SWOT分析
  • 区域细分
    • 根据客户要求，提供主要国家的市场估算和预测以及复合年增长率（註：可行性需确认）。
  • 竞争标竿分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟进行基准分析

目录

第一章执行摘要

第二章 前言

  • 概括
  • 相关利益者
  • 调查范围
  • 调查方法
  • 研究材料

第三章 市场趋势分析

  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球神经发育障碍数位疗法市场（按产品类型划分）

  • 行动应用
  • 软体平台
  • 基于虚拟实境（VR）的治疗方法
  • 穿戴式整合解决方案

6. 全球神经发育障碍数位疗法市场（依疾病类型划分）

  • 注意力不足过动症（ADHD）
  • 泛自闭症障碍（ASD）
  • 阅读障碍与学习障碍
  • 其他类型的故障

7. 全球神经发育障碍数位疗法市场（以最终用户划分）

  • 病人
  • 看护者
  • 医疗保健提供者
  • 付款方/保险公司

8. 全球神经发育障碍数位疗法市场（按地区划分）

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章：重大进展

  • 协议、伙伴关係、合作和合资企业
  • 併购
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十章：企业概况

  • Akili Interactive Labs
  • Cognoa
  • NeuroSigma
  • Atenxia
  • Braingaze
  • Tali Digital
  • Neurotech International
  • Sincrolab
  • Poppins
  • Limbix
  • Floreo
  • Rethink Autism
  • Elemy
  • Mightier
  • Revibe Technologies
Product Code: SMRC33480

According to Stratistics MRC, the Global Digital Therapeutics for Neurodevelopmental Disorders Market is accounted for $48.0 million in 2025 and is expected to reach $204.44 million by 2032 growing at a CAGR of 23.0% during the forecast period. Digital therapeutics designed for neurodevelopmental disorders utilize technology-based programs to support improvements in behavior, cognition, and emotional regulation in individuals with conditions like ADHD, autism, and learning disabilities. These validated digital tools deliver customized interventions via mobile apps, virtual reality experiences, and gamified exercises, allowing continuous assessment and instant feedback. Serving as a complement to conventional therapies, they increase patient participation and provide flexible, remote-accessible care. The rising use of these solutions in clinics and homes is enhancing early treatment, adherence, and overall outcomes, offering data-informed guidance that transforms how neurodevelopmental conditions are monitored and managed effectively.

According to a meta-analysis of 31 studies involving 2,169 children and adolescents with ADHD, digital therapeutic interventions significantly improved inattention symptoms and reaction time while enhancing executive function and working memory compared with control groups, indicating potential clinical benefit.

Market Dynamics:

Driver:

Rising awareness and acceptance among caregivers and clinicians

Increasing knowledge and acceptance of digital therapeutics among parents, caregivers, and medical professionals are boosting market growth. Evidence from clinical trials and successful patient outcomes enhances confidence in these interventions. Caregivers value accessible, remote, and efficient treatment options, while clinicians see them as valuable complements to standard therapies. Rising trust and endorsement by healthcare providers drive adoption and stimulate further R&D, supporting the broader integration of technology-based treatments for neurodevelopment disorders and encouraging market expansion.

Restraint:

Limited clinical validation and regulatory challenges

A significant challenge limiting the growth of digital therapeutics for neurodevelopmental disorders is insufficient long-term clinical evidence and unclear regulatory pathways. Numerous solutions have limited validation, making healthcare professionals cautious about recommending them. Regulatory inconsistencies across countries create uncertainty around approvals, reimbursement policies, and legal compliance. As clinicians prioritize established, clinically proven therapies, adoption of digital alternatives remains slow. Additionally, the lack of standardized assessment methods reduces confidence in treatment outcomes. These regulatory and validation gaps delay commercialization and restrict broader acceptance of digital therapeutics within traditional healthcare systems.

Opportunity:

Expansion of telehealth and remote care models

The growing acceptance of telehealth and virtual care creates strong growth opportunities for digital therapeutics in neurodevelopmental disorder management. Digital platforms enable therapy delivery beyond hospitals, allowing patients to receive personalized interventions at home. This model supports consistent monitoring, early diagnosis, and ongoing treatment while minimizing travel and infrastructure constraints. Improved access benefits rural and underserved communities, expanding market reach. As remote healthcare becomes mainstream, digital therapeutics can integrate easily into telemedicine frameworks, driving broader adoption and strengthening long-term care strategies for neurodevelopmental conditions.

Threat:

Competition from traditional therapies and alternative treatments

A major threat to digital therapeutics is the dominance of traditional treatment methods, including behavioral and pharmacological therapies, which are already trusted and routinely prescribed. Healthcare professionals and caregivers often favor in-person interventions because of long-standing clinical validation and established care pathways. The presence of alternative and complementary therapies adds further pressure, making it challenging for digital solutions to gain acceptance. This strong competition can restrict adoption rates, reduce patient willingness to switch, and slow the overall growth of digital therapeutics in neurodevelopmental disorder care.

Covid-19 Impact:

The outbreak of COVID-19 had a strong positive influence on the digital therapeutics market for neurodevelopmental disorders by shifting care delivery toward remote solutions. Restrictions on physical interactions disrupted traditional therapy services, creating an urgent need for home-based and virtual treatment options. Digital therapeutics emerged as effective tools for maintaining therapy routines, tracking patient progress, and supporting caregivers during extended lockdowns. Increased focus on mental and developmental health further boosted acceptance of technology-driven care. The pandemic prompted faster adoption, higher funding, and greater regulatory openness, reinforcing the role of digital therapeutics as essential components of future neurodevelopmental disorder management.

The mobile applications segment is expected to be the largest during the forecast period

The mobile applications segment is expected to account for the largest market share during the forecast period because they are highly convenient and widely accessible. Designed to run on commonly used smart phones and tablets, these solutions deliver personalized therapeutic activities focused on behavior, cognition, and emotional development. Their user-friendly nature allows children, caregivers, and clinicians to engage consistently with therapy outside traditional care settings. Mobile apps also support ongoing progress tracking and remote supervision, enhancing treatment continuity. Due to their simplicity, adaptability, and strong user engagement, mobile applications are preferred over more complex technologies, securing the leading position within this digital therapeutics market.

The patients segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the patients segment is predicted to witness the highest growth rate for neurodevelopmental disorders as individuals increasingly engage directly with technology-enabled therapy solutions. Easy access to smart phones and digital platforms allows patients to participate actively in their treatment beyond traditional healthcare settings. Interactive and customized therapeutic content enhances engagement and long-term adherence. As patient empowerment and home-based care gain importance, demand for convenient and flexible digital therapies continues to rise. Improved awareness, higher comfort with digital health tools, and a focus on personalized care models are accelerating adoption, positioning patients as the segment with the highest growth potential.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by advanced healthcare systems and rapid adoption of digital health technologies. High penetration of smart devices, well-established telemedicine frameworks, and strong clinician awareness drive widespread use of digital therapies. Favorable policy support, continuous innovation, and significant investment in pediatric and mental health solutions contribute to regional leadership. Emphasis on early intervention and personalized care further boosts adoption. These factors collectively enable strong market presence and sustained leadership, making North America the largest contributor to global digital therapeutics adoption in neurodevelopmental care.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by accelerating digital adoption and healthcare modernization. Widespread use of mobile devices and improved connectivity enable broader access to app-based and remote therapeutic solutions. Increasing recognition of developmental disorders, along with supportive digital health programs, is encouraging adoption among caregivers and providers. The region's large pediatric population and need for affordable, scalable care solutions further fuel expansion. These factors collectively position Asia-Pacific as the highest-growth market for digital therapeutics.

Key players in the market

Some of the key players in Digital Therapeutics for Neurodevelopmental Disorders Market include Akili Interactive Labs, Cognoa, NeuroSigma, Atenxia, Braingaze, Tali Digital, Neurotech International, Sincrolab, Poppins, Limbix, Floreo, Rethink Autism, Elemy, Mightier and Revibe Technologies.

Key Developments:

In January 2026, NeuroSigma, Inc. announced the completion of an approximately $1-million investment into a high-volume manufacturing line in partnership with Singapore-based Armstrong Asia. The investment was led by Pasadena-based strategic advisory and investment group Checkmate Capital.

In May 2024, Akili has signed a definitive merger agreement with mental health and fitness company Virtual Therapeutics in a deal reportedly worth $34 million. Under the agreement, which is slated to close in the third quarter of 2024, Akili shareholders will receive $0.4340 per share of common stock in cash.

Product Types Covered:

  • Mobile Applications
  • Software Platforms
  • Virtual Reality (VR)-based Therapies
  • Wearable-integrated Solutions

Disorder Types Covered:

  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Autism Spectrum Disorder (ASD)
  • Dyslexia & Learning Disabilities
  • Other Disorder Types

End Users Covered:

  • Patients
  • Caregivers
  • Healthcare Providers
  • Payers / Insurance Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Digital Therapeutics for Neurodevelopmental Disorders Market, By Product Type

  • 5.1 Introduction
  • 5.2 Mobile Applications
  • 5.3 Software Platforms
  • 5.4 Virtual Reality (VR)-based Therapies
  • 5.5 Wearable-integrated Solutions

6 Global Digital Therapeutics for Neurodevelopmental Disorders Market, By Disorder Type

  • 6.1 Introduction
  • 6.2 Attention Deficit Hyperactivity Disorder (ADHD)
  • 6.3 Autism Spectrum Disorder (ASD)
  • 6.4 Dyslexia & Learning Disabilities
  • 6.5 Other Disorder Types

7 Global Digital Therapeutics for Neurodevelopmental Disorders Market, By End User

  • 7.1 Introduction
  • 7.2 Patients
  • 7.3 Caregivers
  • 7.4 Healthcare Providers
  • 7.5 Payers / Insurance Companies

8 Global Digital Therapeutics for Neurodevelopmental Disorders Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Akili Interactive Labs
  • 10.2 Cognoa
  • 10.3 NeuroSigma
  • 10.4 Atenxia
  • 10.5 Braingaze
  • 10.6 Tali Digital
  • 10.7 Neurotech International
  • 10.8 Sincrolab
  • 10.9 Poppins
  • 10.10 Limbix
  • 10.11 Floreo
  • 10.12 Rethink Autism
  • 10.13 Elemy
  • 10.14 Mightier
  • 10.15 Revibe Technologies

List of Tables

  • Table 1 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Mobile Applications (2024-2032) ($MN)
  • Table 4 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Software Platforms (2024-2032) ($MN)
  • Table 5 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Virtual Reality (VR)-based Therapies (2024-2032) ($MN)
  • Table 6 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Wearable-integrated Solutions (2024-2032) ($MN)
  • Table 7 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Disorder Type (2024-2032) ($MN)
  • Table 8 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Attention Deficit Hyperactivity Disorder (ADHD) (2024-2032) ($MN)
  • Table 9 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Autism Spectrum Disorder (ASD) (2024-2032) ($MN)
  • Table 10 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Dyslexia & Learning Disabilities (2024-2032) ($MN)
  • Table 11 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Other Disorder Types (2024-2032) ($MN)
  • Table 12 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By End User (2024-2032) ($MN)
  • Table 13 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Patients (2024-2032) ($MN)
  • Table 14 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Caregivers (2024-2032) ($MN)
  • Table 15 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Healthcare Providers (2024-2032) ($MN)
  • Table 16 Global Digital Therapeutics for Neurodevelopmental Disorders Market Outlook, By Payers / Insurance Companies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.